Literature DB >> 36255616

Defined Human Leukemic CD34+ Liquid Cultures to Study HDAC/Transcriptional Repressor Complexes.

Roland Windisch1, Sophie Kreissig1, Christian Wichmann2.   

Abstract

Defined human primary cell model systems with growth dependence on oncogenes are highly requested to investigate tumor pathogenesis and to validate pharmacological inhibitors that specifically target oncoproteins and their executing protein complex partners. In acute myeloid leukemia (AML), transcription factors such as RUNX1 and MLL1, which are important for normal blood cell development, frequently harbor mutations including chromosomal translocations with other coding genes, resulting in tumor-promoting gain-of-function fusion proteins. These oncoproteins completely modify transcriptional programs, thereby inducing malignant cell phenotypes. A common theme of the chimeric gene products is their physical interaction with a variety of chromatin-modifying effector molecules, including histone acetyltransferases (HATs) and histone deacetylases (HDACs). These aberrant multiprotein machineries disturb gene expression and promote malignant cell growth. In this chapter, we briefly summarize the current understanding regarding AML-associated oncogene-driven human CD34+ blood progenitor cell expansion in ex vivo liquid cultures. We provide a step-by-step protocol to establish oncogene-induced human CD34+ blood progenitor cell cultures suitable to analyze the impact of transcriptional repressor/HDAC activity in these human AML cell models.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CD34+; Histone deacetylase; Human blood progenitor; MLL; Progenitor expansion; RUNX1

Mesh:

Substances:

Year:  2023        PMID: 36255616     DOI: 10.1007/978-1-0716-2788-4_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  59 in total

1.  Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription.

Authors:  H Nakajima; P K Brindle; M Handa; J N Ihle
Journal:  EMBO J       Date:  2001-12-03       Impact factor: 11.598

2.  Genomic landscapes and clonality of de novo AML.

Authors:  Christopher A Miller; Richard K Wilson; Timothy J Ley
Journal:  N Engl J Med       Date:  2013-10-10       Impact factor: 91.245

3.  Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.

Authors:  Serena Racanicchi; Chiara Maccherani; Concetta Liberatore; Monia Billi; Vania Gelmetti; Maddalena Panigada; Giovanni Rizzo; Clara Nervi; Francesco Grignani
Journal:  EMBO J       Date:  2005-02-24       Impact factor: 11.598

4.  Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.

Authors:  F Grignani; S De Matteis; C Nervi; L Tomassoni; V Gelmetti; M Cioce; M Fanelli; M Ruthardt; F F Ferrara; I Zamir; C Seiser; F Grignani; M A Lazar; S Minucci; P G Pelicci
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

Review 5.  Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.

Authors:  A Quintás-Cardama; F P S Santos; G Garcia-Manero
Journal:  Leukemia       Date:  2010-11-30       Impact factor: 11.528

6.  The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex.

Authors:  Alexander B Maurer; Christian Wichmann; Alexandra Gross; Hana Kunkel; Thorsten Heinzel; Martin Ruthardt; Bernd Groner; Manuel Grez
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

7.  Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.

Authors:  Shuo Dong; David J Tweardy
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

Review 8.  The roles of FLT3 in hematopoiesis and leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

9.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Giuseppe Avvisati; Marco Vignetti; Christian Thiede; Sonia Maria Orlando; Simona Iacobelli; Felicetto Ferrara; Paola Fazi; Laura Cicconi; Eros Di Bona; Giorgina Specchia; Simona Sica; Mariadomenica Divona; Alessandro Levis; Walter Fiedler; Elisa Cerqui; Massimo Breccia; Giuseppe Fioritoni; Helmut R Salih; Mario Cazzola; Lorella Melillo; Angelo M Carella; Christian H Brandts; Enrica Morra; Marie von Lilienfeld-Toal; Bernd Hertenstein; Mohammed Wattad; Michael Lübbert; Matthias Hänel; Norbert Schmitz; Hartmut Link; Maria Grazia Kropp; Alessandro Rambaldi; Giorgio La Nasa; Mario Luppi; Fabio Ciceri; Olimpia Finizio; Adriano Venditti; Francesco Fabbiano; Konstanze Döhner; Michaela Sauer; Arnold Ganser; Sergio Amadori; Franco Mandelli; Hartmut Döhner; Gerhard Ehninger; Richard F Schlenk; Uwe Platzbecker
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

10.  Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.

Authors:  Kiyomi Morita; Feng Wang; Katharina Jahn; Tianyuan Hu; Tomoyuki Tanaka; Yuya Sasaki; Jack Kuipers; Sanam Loghavi; Sa A Wang; Yuanqing Yan; Ken Furudate; Jairo Matthews; Latasha Little; Curtis Gumbs; Jianhua Zhang; Xingzhi Song; Erika Thompson; Keyur P Patel; Carlos E Bueso-Ramos; Courtney D DiNardo; Farhad Ravandi; Elias Jabbour; Michael Andreeff; Jorge Cortes; Kapil Bhalla; Guillermo Garcia-Manero; Hagop Kantarjian; Marina Konopleva; Daisuke Nakada; Nicholas Navin; Niko Beerenwinkel; P Andrew Futreal; Koichi Takahashi
Journal:  Nat Commun       Date:  2020-10-21       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.